New Genetic Test Guidance Narrows Focus To Mutation Marker Assays
This article was originally published in The Gray Sheet
Executive Summary
FDA is narrowing the focus of its proposed guidelines for manufacturers of gene-based tests from its original 2003 draft in response to comments from industry members and scientists, according to a revised 1draft guidance document issued Feb. 9
You may also be interested in...
Final FDA Genetic Test Guidelines Respond To Some Industry Critiques
FDA finalized guidelines for developing gene-based tests June 19, responding to some industry concerns with a February 2006 proposal, but largely sticking with the intent of the earlier draft
Final FDA Genetic Test Guidelines Respond To Some Industry Critiques
FDA finalized guidelines for developing gene-based tests June 19, responding to some industry concerns with a February 2006 proposal, but largely sticking with the intent of the earlier draft
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance